Allarity Therapeutics获得纳斯达克批准的延期以恢复合规性

2024-04-17 21:19

Allarity Therapeutics (NASDAQ: ALLR) announced that it had been granted an extension until May 14, 2024, to regain compliance with Nasdaq.
Allarity Therapeutics presented a strategic plan to the Nasdaq Hearings Panel, detailing both immediate and long-term strategies aimed at regaining compliance with the requirements outlined in Nasdaq Listing Rules.
These efforts include ongoing cost reduction initiatives, reducing monthly operational expenditures from over $1 million to $400,000.
In addition, the company entered into negotiations with key stakeholders, to adjust the terms and conditions to make future capital raising more amenable, as well as negotiations to reduce other major liabilities.
Finally, the company has already started raising new equity by utilizing its existing ATM and expects to take further action so Allarity can meet the $2.5M equity requirement on the May 14, 2024 target date.
Source: Press Release

More on Allarity Therapeutics